IP Library Granted Patent US 10,881,736
Granted Patent B2
US 10,881,736 · App. 14/901,246 · Granted Jan 5, 2021

Biophotonic compositions comprising a chromophore and a gelling agent for treating wounds

Inventors: Nikolaos Loupis (Athens, GR); Remigio Piergallini (A.P., IT); Shipra Rastogi (Laval, CA)
Assignee: KLOX TECHNOLOGIES INC.
A61K41/0057A61K41/0038A61L26/0066A61N5/062C09K11/06A61N2005/0662C09K2211/1011C09K2211/1088
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,881,736
App. No.
14/901,246
Granted
Jan 5, 2021
Kind
B2
Abstract

The present disclosure provides biophotonic compositions, kits and their uses. In particular, the biophotonic compositions of the present disclosure are substantially resistant to leaching such that low amounts of chromophores present in the biophotonic composition leach out of the composition. The biophotonic compositions and their uses are useful for promoting repair of non-healing wounds.

Claims (36)

1. A method for stimulating repair of a Grade II chronic wound, or of a Grade III chronic wound, or both, to generate a closed wound without a hollow under a surface of the closed wound, comprising:

applying topically a biophotonic composition to the Grade II chronic wound, or to the Grade III chronic wound, or to both; wherein the biophotonic composition comprises:

at least a first chromophore; and

a gelling agent present in an amount sufficient to gel the composition and render the biophotonic composition substantially resistant to leaching such that less than 15% by weight of the total chromophore amount leaches out of the biophotonic composition in use, and such that the biophotonic composition has a viscosity of between about 10,000 cP and about 50,000 cP; and

illuminating the applied biophotonic composition with a light source emitting a light having a wavelength that overlaps with an absorption spectrum of the first chromophore and a power density of between about 50-150 mW/cm 2 at a distance of about 5 cm from the light source.

2. The method of claim 1 , wherein the gelling agent is one or more of a cross-linked polymer, a hydrophilic material, a hygroscopic material or a hydrated polymer.

3. The method of claim 1 , for further stimulating repair at the edge of the Grade II chronic wound, or of the Grade III chronic wound, or both.

4. The method of claim 3 , wherein the stimulated repair is delayed at the edge compared to the wound base of the Grade II chronic wound, or of the Grade III chronic wound, or both.

5. The method of claim 4 , wherein the stimulated repair is increased at the wound base compared to the edge of the Grade II chronic wound, or of the Grade III chronic wound, or both.

6. The method of claim 3 , wherein stimulating repair comprises inducing expression of growth factors or cytokines or both.

7. The method of claim 6 , wherein the induced growth factor expression is different at the wound base than at edge of the Grade II chronic wound, or of the Grade III chronic wound, or both.

8. The method of claim 3 , wherein stimulating repair comprises attracting repair cell progenitors and/or repair cells to the centre of the Grade II chronic wound, or of the Grade III chronic wound, or both.

9. The method of claim 8 , wherein repair cells comprise fibroblasts, keratinocytes or endothelial cells.

10. The method of claim 1 , wherein the Grade II chronic wound, or the Grade III chronic wound, or both, are activated Grade II chronic wound, or activated Grade III chronic wound, or both.

11. The method of claim 1 , wherein the healing of the Grade II chronic wound, or of the Grade III chronic wound, or of both comprises increasing collagen expression.

12. The method of claim 11 , wherein the collagen is collagen I, collagen III and/or procollagen.

13. The method of claim 1 , wherein the healing of the Grade II chronic wound, or of the Grade III chronic wound, or of both comprises inducing granulation in the absence of surgical trauma.

14. The method of claim 1 , wherein the healing of the Grade II chronic wound, or of the Grade III chronic wound, or of both comprises at least one of inducing angiogenesis, epithelialization and remodelling.

15. The method of claim 1 , wherein the light is visible non-coherent light.

16. The method of claim 1 , wherein the applying and illuminating steps are performed at least once, twice or three times a week, for a period of 1 week to 24 weeks.

17. A method for stimulating collagen formation at a Grade II chronic wound, a Grade III chronic wound, or at both to generate a closed wound without a hollow under a surface of the closed wound comprising:

applying topically a biophotonic composition to the Grade II chronic wound, the Grade III chronic wound, or to both; wherein the biophotonic composition comprises:

at least a first chromophore; and

a gelling agent present in an amount sufficient to gel the composition and render the biophotonic composition substantially resistant to leaching such that less than 15% by weight of the total chromophore amount leaches out of the biophotonic composition in use, and such that the biophotonic composition has a viscosity of between about 10,000 cP and about 50,000 cP; and

illuminating the applied biophotonic composition with a light source emitting a light having a wavelength that overlaps with an absorption spectrum of the first chromophore and a power density of between about 50-150 mW/cm 2 at a distance of about 5 cm from the light source.

18. The method of claim 17 , further comprising removing the biophotonic composition after illumination.

19. The method of claim 17 , wherein the biophotonic composition is illuminated for 1 minute to 30 minutes.

20. A method for stimulating repair of a Grade II chronic wound, a Grade III chronic wound, or both, to generate a closed wound without a hollow under a surface of the closed wound, comprising:

topically applying to the Grade II chronic wound, the Grade III chronic wound, or to both a biophotonic composition followed by illumination of the biophotonic composition applied at the wound base with an actinic light source emitting a light having a power density of between about 50-150 mW/cm 2 at a distance of about 5 cm from the light source, wherein the biophotonic composition comprises:

at least a first chromophore; and

a gelling agent present in an amount sufficient to gel the composition and render the biophotonic composition substantially resistant to leaching such that less than 15% by weight of the total chromophore amount leaches out of the biophotonic composition in use, and such that the biophotonic composition has a viscosity of between about 10,000 cP and about 50,000 cP; and

wherein the method comprises the following schedule:

(a) a period of from 1 day to 24 weeks during which said biophotonic composition is topically applied to the Grade II chronic wound, the Grade III chronic wound, or to both, followed by

(b) a rest period of from 3 days to 30 days; and

(c) repeating at least (a) until wound closure.

21. The method of claim 20 , wherein the period of (a) continues until a slow-down of the wound healing response is observed.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2023
From: KLOX TECHNOLOGIES INC.
To: FLE INTERNATIONAL S.R.L.
Reel/Frame 063214/0370 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2016
From: LOUPIS, NIKOLAOS; PIERGALLINI, REMIGIO
To: KLOX TECHNOLOGIES INC.
Reel/Frame 039029/0476 →
EMPLOYMENT AGREEMENT Recorded Jun 28, 2016
From: RASTOGI, SHIPRA
To: KLOX TECHNOLOGIES INC.
Reel/Frame 039194/0961 →
Continuity (3)
Provisional Application 61904204 · Nov 14, 2013
Provisional Application 61842433 · Jul 3, 2013
Related Publication 20160193338A1 · Jul 7, 2016